Folfox plus Bevacizumab and reolysin — Competitive Intelligence Brief

Folfox plus Bevacizumab and reolysin (Folfox plus Bevacizumab and reolysin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy regimen. Area: Oncology.

phase 2 chemotherapy regimen VEGF, thymidylate synthase, DNA repair Oncology Small molecule

Target snapshot

Folfox plus Bevacizumab and reolysin (Folfox plus Bevacizumab and reolysin) — Canadian Cancer Trials Group. Folfox plus Bevacizumab and reolysin is a combination chemotherapy regimen that targets rapidly dividing cancer cells and inhibits angiogenesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Folfox plus Bevacizumab and reolysin TARGET	Folfox plus Bevacizumab and reolysin	Canadian Cancer Trials Group	phase 2	chemotherapy regimen	VEGF, thymidylate synthase, DNA repair
TAC chemotherapy	TAC chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)
Carboplatin, Etoposide, Ifosfamide	Carboplatin, Etoposide, Ifosfamide	University Hospital Muenster	marketed	Combination chemotherapy regimen	DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition)
Adjuvant chemotherapy	Adjuvant chemotherapy	Institut de Cancérologie de Lorraine	marketed	Chemotherapy regimen (multi-agent or single-agent cytotoxic)
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
TCH chemotherapy	TCH chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)	HER2, microtubule, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy regimen class)

1. University Hospital, Grenoble · 2 drugs in this class
2. Canadian Cancer Trials Group · 1 drug in this class
3. Centre Georges Francois Leclerc · 1 drug in this class
4. Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 drug in this class
5. French Innovative Leukemia Organisation · 1 drug in this class
6. AIO-Studien-gGmbH · 1 drug in this class
7. GlaxoSmithKline · 1 drug in this class
8. National Research Center for Hematology, Russia · 1 drug in this class
9. Ospedale Santa Croce-Carle Cuneo · 1 drug in this class
10. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class